ADC Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for ADC Therapeutics (ADCT).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

3Buy

3Hold

Consensus RatingOverweight# Analysts6Avg. Consensus PT$6Upside to Avg. PT+238.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$10→$5
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	—
Jun 4, 2026	RBC Capital	Leonid Timashev	Downgrade	Outperform→Sector Perform	$6→$2
May 5, 2026	RBC Capital	Leonid Timashev	Maintained	Outperform	$6
May 5, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8
Mar 23, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$7→$8
Oct 16, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$8→$7
Aug 13, 2025	Guggenheim	Michael Schmidt	Maintained	Buy	$10
Jun 20, 2025	RBC Capital	Leonid Timashev	PT Cut	Outperform	$8→$5
Jun 13, 2025	Guggenheim	Michael Schmidt	PT Raise	Buy	$7→$10
May 15, 2025	RBC Capital	Gregory Renza	Maintained	Outperform	$8
Mar 31, 2025	Guggenheim	Michael Schmidt	PT Cut	Buy	$10→$7
Mar 31, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8
Mar 7, 2025	Cantor Fitzgerald	Eric Schmidt	Maintained	Overweight	—
Feb 24, 2025	Stephens & Co.	Sudan Loganathan	PT Raise	Overweight	$6→$8
Jan 6, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8
Dec 12, 2024	Guggenheim	Michael Schmidt	Maintained	Buy	$10
Dec 11, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	—
Nov 8, 2024	Stephens & Co.	Sudan Loganathan	Initiate	Overweight	$6
Aug 8, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.

Benzinga Newsdesk

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades ADC Therapeutics (NYSE:ADCT) from Buy to Neutral.

Benzinga Newsdesk

PRO
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Sector Perform and lowers the price target from $6 to $2.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $6 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.

Benzinga Newsdesk

ADC Therapeutics SA

ニュース

パートナーシップ

ベンジンガ・グローバル

ADC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

PRO
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

PRO
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

PRO
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

ADC Therapeutics SA

ニュース

パートナーシップ

ベンジンガ・グローバル

ADC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

PROHC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

PRORBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

PRORBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

PROHC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

PRO
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

PRO
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

PRO
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target